GO:0070858 negative regulation of bile acid biosynthetic process: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070858 describes any process that stops, prevents, or reduces the frequency, rate or extent of bile acid biosynthesis, a core liver metabolic pathway.
• The farnesoid X receptor (FXR, NR1H4) is the central nuclear receptor that senses elevated bile acids and feeds back to suppress their own synthesis.
• Gut microbiota shape this negative regulation by converting primary bile acids into secondary species and by altering FXR antagonist pools such as tauro-beta-muricholic acid.
• Loss of negative feedback causes hypercholanemia and cholestatic injury, as shown for SLC10A5 deficiency and in cholestasis-associated inflammation models.
• Bile acid signaling is now recognized as a modifier of cancer immunity and systemic metabolism, making this GO term relevant beyond hepatology.
• CRISPR knockout, point-mutation, knock-in and overexpression models are the standard tools to test causality within this regulatory axis.
Description
GO:0070858, negative regulation of bile acid biosynthetic process, is a biological_process term that captures the cellular logic by which bile acid production is switched down. Bile acids are amphipathic molecules synthesized from cholesterol in hepatocytes; when their concentration rises, dedicated feedback circuits reduce the transcription and activity of biosynthetic enzymes so that the bile acid pool stays within a physiological window. This term therefore sits at the intersection of nuclear receptor signaling, hepatic metabolism and microbiome-host communication. For researchers, GO:0070858 is a useful annotation target because it is mechanistically defined rather than merely descriptive. The best-characterized arm is farnesoid X receptor (FXR, NR1H4) signaling: bile acids activate FXR, and activated FXR represses the rate-limiting biosynthetic enzyme CYP7A1, thereby closing a negative feedback loop. Additional layers include intestinal FXR-TGR5 crosstalk, microbiota-dependent modification of bile acid pools, and transporter-mediated control of hepatic bile acid load. Because failure of this negative regulation leads to cholestasis, hypercholanemia and inflammation, the term is directly relevant to liver disease, metabolic disease and even tumor immunology. This article summarizes the verified literature on GO:0070858, lists the genes and proteins that carry it out, and outlines CRISPR-based strategies for dissecting the pathway.
negative regulation of bile acid biosynthetic process At A Glance
| GO ID | GO:0070858 |
|---|---|
| GO term | negative regulation of bile acid biosynthetic process |
| Ontology | biological_process |
| Synonym | none listed in QuickGO |
| Major function | Suppression of bile acid biosynthesis to maintain bile acid homeostasis |
| Central regulator | FXR (NR1H4) negative feedback on CYP7A1 and related enzymes |
| Microbiome input | Microbial bile acid modification alters FXR antagonist/agonist balance |
| Disease link | Cholestasis, hypercholanemia, inflammation and bile acid-driven cancer biology |
| Experimental readout | Bile acid pool size, FXR target gene expression, and cholestasis markers |
What Is GO:0070858?
In our own words, GO:0070858 refers to any biological process that decreases the rate, frequency or extent of bile acid biosynthesis. It does not describe the biosynthetic enzymes themselves, but rather the inhibitory inputs that act on them, such as nuclear receptor-mediated transcriptional repression, microbiota-driven changes in bile acid pools, and signaling events that lower the effective drive on the cholesterol-to-bile-acid conversion pathway.
Why Is negative regulation of bile acid biosynthetic process Important in Cell Biology?
GO:0070858 matters because bile acid biosynthesis is a high-flux, potentially toxic pathway that must be restrained. When negative regulation fails, bile acids accumulate and drive cholestatic liver injury, hypercholanemia and systemic inflammation. Conversely, excessive suppression or altered bile acid composition changes metabolic and immune signaling, with consequences for obesity, glucose control and tumor immunity. Understanding this term therefore helps researchers connect nuclear receptor biology, gut microbiota and disease phenotypes in a single mechanistic framework.
• Maintains bile acid homeostasis and prevents cholestatic liver injury.
• Defines the FXR-CYP7A1 negative feedback loop, a textbook example of metabolic feedback.
• Links gut microbiota composition to host bile acid pool size and composition.
• Explains how gastric bypass and diet-induced obesity alter systemic glucose control via FXR-TGR5 crosstalk.
• Provides a mechanistic basis for hypercholanemia caused by transporter deficiency such as SLC10A5.
• Connects bile acid signaling to inflammation through the NLRP3 inflammasome in cholestasis-associated sepsis.
• Shapes anti-tumor immunity because microbiota-modified bile acids can suppress CD8+ T cell effector functions.
• Offers druggable nodes (FXR, TGR5, transporters) for metabolic and liver disease research.
• Requires careful model selection because hepatic and intestinal contributions differ.
• Is a tractable CRISPR target set for causal testing of candidate regulators.
What Happens During negative regulation of bile acid biosynthetic process?
Bile acid sensing by FXR
In simple terms: When bile acids build up, a sensor protein called FXR detects them and starts a shutdown signal.
The initiating event in the canonical negative feedback arm is bile acid binding to the nuclear receptor FXR (NR1H4). Elevated bile acids activate FXR, which then changes the transcription of target genes that control bile acid synthesis and transport. This sensing step is what converts a metabolic surplus into a regulatory output, and it is the reason GO:0070858 is tightly coupled to bile acid pool size.
Transcriptional repression of biosynthetic enzymes
In simple terms: The shutdown signal reduces the production of the enzymes that make bile acids.
Activated FXR represses the rate-limiting enzyme CYP7A1 and related biosynthetic genes, lowering the conversion of cholesterol into bile acids. This transcriptional repression is the effector step that directly satisfies the definition of GO:0070858, because it reduces the frequency and extent of bile acid biosynthesis.
Microbiota-dependent modulation of the feedback set point
In simple terms: Gut bacteria chemically modify bile acids, which changes how strongly the shutdown signal is triggered.
The intestinal microbiota deconjugate and transform primary bile acids, altering the abundance of FXR agonists and antagonists such as tauro-beta-muricholic acid. Because these microbial products change FXR activity, the microbiota effectively tunes the set point of negative regulation of bile acid biosynthesis. Host metabolism and microbial regulation are therefore balanced rather than independent.
Intestinal FXR-TGR5 crosstalk and systemic metabolic output
In simple terms: Signals from the intestine talk to the rest of the body and influence how bile acids are handled.
Intestinal FXR and TGR5 signaling relay bile acid status to peripheral tissues, and functional changes in the gastric bypass microbiota can reactivate thermogenic adipose tissue and improve systemic glucose control through this crosstalk. This shows that negative regulation of bile acid biosynthesis is not an isolated hepatic event but part of an inter-organ communication network.
Transporter-dependent control of hepatic bile acid load
In simple terms: Transport proteins determine how much bile acid stays in the liver, which in turn affects the shutdown signal.
Hepatic bile acid load is a key input into the feedback loop, and transporter defects can break the system. SLC10A5 deficiency causes hypercholanemia, demonstrating that impaired bile acid handling disrupts the normal negative regulation of bile acid biosynthesis and leads to accumulation. This provides genetic evidence that the regulatory term has direct physiological consequences when its inputs fail.
Inflammatory consequences when negative regulation fails
In simple terms: If bile acids are not shut down properly, they can trigger harmful inflammation.
FXR regulation of the NLRP3 inflammasome underlies cholestasis-associated sepsis, linking failed bile acid feedback to inflammatory pathology. In parallel, TREM-2 acts as a negative regulator of inflammation in cholestasis, showing that protective anti-inflammatory circuits intersect with bile acid stress. Together these studies indicate that GO:0070858 is mechanistically connected to inflammatory disease outcomes.
Key Genes Involved in GO:0070858 negative regulation of bile acid biosynthetic process
The following genes and proteins are the principal experimentally supported participants in negative regulation of bile acid biosynthetic process and its physiological context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NR1H4 (FXR) | Nuclear receptor that senses bile acids and represses biosynthesis | Central regulator of the negative feedback loop |
| CYP7A1 | Rate-limiting enzyme of bile acid biosynthesis and FXR repression target | Readout of pathway suppression |
| TGR5 (GPBAR1) | Membrane bile acid receptor mediating intestinal and systemic signaling | Node in FXR-TGR5 crosstalk |
| SLC10A5 | Transporter influencing hepatic bile acid handling | Deficiency causes hypercholanemia |
| NLRP3 | Inflammasome component downstream of FXR regulation | Links bile acid feedback to cholestasis-associated sepsis |
| TREM2 | Negative regulator of inflammation in cholestasis | Protective role in cholestatic liver injury |
| CYP8B1 | Bile acid biosynthetic enzyme contributing to pool composition | Context for feedback repression |
| CYP27A1 | Alternative pathway bile acid biosynthetic enzyme | Context for feedback repression |
| FGF19 (human) / FGF15 (mouse) | Intestinal FXR target hormone that represses hepatic CYP7A1 | Mediator of gut-liver negative feedback |
| SHP (NR0B2) | FXR-induced nuclear corepressor of CYP7A1 | Transcriptional effector of negative regulation |
| ASBT (SLC10A2) | Intestinal bile acid transporter | Determines intestinal bile acid signaling input |
| OST-alpha/OST-beta | Basolateral bile acid efflux transporters | Context for bile acid pool regulation |
| BSEP (ABCB11) | Canalicular bile acid export pump | Cholestasis-relevant transporter |
| MRP2 (ABCC2) | Canalicular organic anion transporter | Cholestasis-relevant transporter |
| CD8+ T cells (marker genes) | Effector immune cells suppressed by microbiota-modified bile acids | Links bile acid biology to tumor immunity |
| Gut microbiota taxa | Modify bile acids and FXR antagonist pools | Environmental regulator of the feedback set point |
How Is negative regulation of bile acid biosynthetic process Regulated?
Negative regulation of bile acid biosynthetic process is itself regulated at multiple levels. The dominant layer is nuclear receptor feedback: bile acid activation of FXR induces repressive factors and reduces CYP7A1 transcription, closing the loop. A second layer is microbial: gut bacteria modify bile acids and change the balance of FXR agonists and antagonists such as tauro-beta-muricholic acid, thereby resetting the sensitivity of the feedback system. A third layer is inter-organ signaling, in which intestinal FXR-TGR5 crosstalk communicates bile acid status to adipose tissue and glucose-regulatory circuits. Finally, transporter capacity sets the hepatic bile acid load that feeds into the sensor, as illustrated by hypercholanemia in SLC10A5 deficiency. Together these layers determine how strongly bile acid biosynthesis is suppressed at any moment.
negative regulation of bile acid biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC10A5 | Hypercholanemia | Knockout mouse or hepatocyte KO to test bile acid accumulation |
| NR1H4 (FXR) | Cholestasis-associated sepsis and bile acid feedback failure | Conditional KO and point-mutation models of ligand binding |
| NLRP3 | Inflammation in cholestasis-associated sepsis | Knockout and knock-in reporter models |
| TREM2 | Cholestatic liver injury and inflammation | Knockout mouse with bile duct ligation or diet challenge |
| Microbiota-modified bile acids | Colorectal cancer growth and CD8+ T cell suppression | Germ-free or antibiotic-treated models plus KO of FXR/TGR5 |
Cholestasis and hypercholanemia
When negative regulation of bile acid biosynthesis is impaired, bile acids accumulate and cause cholestatic injury. SLC10A5 deficiency causes hypercholanemia, directly demonstrating that disrupted bile acid handling breaks the normal feedback restraint. In cholestasis, protective anti-inflammatory circuits such as TREM-2 act as negative regulators of inflammation, and their loss worsens injury. These findings place GO:0070858 at the center of cholestatic disease mechanisms.
Cholestasis-associated sepsis and inflammation
FXR regulation of the NLRP3 inflammasome underlies cholestasis-associated sepsis, showing that the bile acid feedback axis controls inflammatory responses beyond the liver. This connects failure of negative regulation to systemic inflammatory disease and identifies FXR-NLRP3 signaling as a mechanistic bridge. The anti-inflammatory role of TREM-2 in cholestasis reinforces the idea that bile acid stress and inflammation are coupled.
Metabolic disease and obesity
Functional changes in the gastric bypass microbiota reactivate thermogenic adipose tissue and improve systemic glucose control via intestinal FXR-TGR5 crosstalk in diet-induced obesity. This demonstrates that manipulating the bile acid feedback system has measurable metabolic consequences, making GO:0070858 relevant to obesity and glucose homeostasis research. Host metabolism balances microbial regulation of bile acid signaling, so both sides must be considered.
Cancer and anti-tumor immunity
Bile acids modified by the intestinal microbiota promote colorectal cancer growth by suppressing CD8+ T cell effector functions. This links the bile acid pool, which is shaped by negative regulation of biosynthesis, to tumor immune evasion. The finding expands the disease relevance of GO:0070858 into immuno-oncology and microbiome research.
From negative regulation of bile acid biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for FXR-mediated repression of bile acid synthesis? | CRISPR knockout in hepatocyte cell lines or conditional mouse KO |
| Does a specific ligand-binding residue of FXR mediate feedback? | Point-mutation knock-in of NR1H4 |
| Does a transporter variant alter bile acid load and feedback? | Knock-in of SLC10A5 variants |
| Where and when is the regulator expressed during cholestasis? | Tagged knock-in with fluorescent or epitope tag |
| Does forced expression of a regulator suppress bile acid biosynthesis? | Overexpression of FXR, SHP or FGF19 in liver models |
| Does microbiota modification change the feedback set point? | Microbiota transfer or gnotobiotic models combined with KO |
How to Study the negative regulation of bile acid biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS bile acid profiling | Pool size and composition of bile acid species | Assessing feedback output in KO and treatment models |
| RT-qPCR of CYP7A1 and FXR targets | Transcriptional repression of biosynthesis | Testing whether negative regulation is active |
| RNA-seq | Global transcriptional consequences of feedback perturbation | Discovering new regulators within the pathway |
| 16S/metagenomic sequencing | Microbial taxa that modify bile acids | Linking microbiota to feedback set point |
| Immunoblotting and inflammasome assays | NLRP3 activation and inflammatory signaling | Cholestasis-associated inflammation studies |
| Histology and liver injury markers | Cholestatic injury severity | Phenotyping transporter and receptor models |
| CD8+ T cell effector assays | Immune suppression by bile acids | Cancer immunity studies |
| Metabolic phenotyping | Glucose control and adipose thermogenesis | FXR-TGR5 crosstalk in obesity models |
Bile acid quantification
Measuring bile acid pool size and composition is the most direct way to assess negative regulation of bile acid biosynthesis. Studies of FXR feedback, microbiota modification and SLC10A5 deficiency all rely on bile acid measurements to demonstrate pathway output. Mass spectrometry-based profiling distinguishes primary, secondary and conjugated species, which is essential because different bile acids have different FXR agonist or antagonist activity.
Transcriptional readouts of the feedback loop
Because the effector step is transcriptional repression, expression analysis of CYP7A1 and related genes is a standard readout. FXR-dependent repression of biosynthetic enzymes has been demonstrated by measuring these transcripts after bile acid or FXR manipulation. Combining this with FXR target gene panels provides a robust signature of whether negative regulation is active.
Microbiome and metabolite profiling
Since the microbiota tunes the feedback set point, 16S or metagenomic profiling should be paired with bile acid metabolomics. Studies showing that gut microbiota regulate bile acid metabolism by reducing tauro-beta-muricholic acid used exactly this combination. Host metabolism balances microbial regulation of bile acid signaling, so integrated analysis is required for correct interpretation.
Inflammation and immune phenotyping
Because failed negative regulation has inflammatory and immune consequences, phenotyping should include inflammasome and immune cell readouts. FXR regulation of the NLRP3 inflammasome and TREM-2 control of cholestatic inflammation were established with such assays. In cancer contexts, CD8+ T cell effector function assays reveal bile acid-driven immune suppression.
How CRISPR Can Be Used to Study GO:0070858 negative regulation of bile acid biosynthetic process
Knockout
CRISPR knockout is the primary tool for testing whether a candidate gene is required for negative regulation of bile acid biosynthesis. Deleting FXR pathway components or transporters such as SLC10A5 allows direct measurement of bile acid accumulation and loss of feedback repression. Knockout studies in cholestasis models also reveal inflammatory consequences when the feedback axis is broken.
Point Mutation
Point-mutation models are used to dissect specific functional residues, such as ligand-binding or DNA-binding domains of FXR, without deleting the entire protein. This approach distinguishes loss of a particular biochemical activity from loss of protein expression, which is important for interpreting feedback phenotypes.
Knock-in
Knock-in of tags, reporters or disease-associated variants enables precise tracking of regulators in vivo. Tagged knock-in of genes such as TREM2 or FXR allows expression and localization to be monitored during cholestasis. Variant knock-in of transporters like SLC10A5 can test whether specific alleles cause hypercholanemia.
Overexpression
Overexpression models test sufficiency: if a regulator is sufficient to suppress bile acid biosynthesis, forced expression should lower bile acid levels and repress CYP7A1. Overexpression of FXR, SHP or FGF19 has been used to probe this arm of the pathway. Such models complement knockout by establishing directionality of the regulatory relationship.
How EDITGENE Supports negative regulation of bile acid biosynthetic process Research
Researchers studying negative regulation of bile acid biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in suppressing bile acid synthesis, or whether it is merely correlated with pathway activity. Answering that question requires clean genetic models in which the candidate gene is deleted, mutated, tagged or overexpressed in a controlled background. EDITGENE provides these models together with screening and bioinformatics support so that the FXR feedback axis, transporter biology and microbiota-linked regulation can be dissected with publication-grade reagents.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of bile acid biosynthetic process research.
Frequently Asked Questions About negative regulation of bile acid biosynthetic process
What is negative regulation of bile acid biosynthetic process (GO:0070858)?
It is the biological process that reduces the rate or extent of bile acid biosynthesis, most prominently through FXR-mediated feedback repression of biosynthetic enzymes such as CYP7A1.
What genes are involved in negative regulation of bile acid biosynthetic process?
Key genes include NR1H4 (FXR), CYP7A1, SHP (NR0B2), FGF19/FGF15, TGR5, SLC10A5, NLRP3 and TREM2, among others.
How does FXR suppress bile acid synthesis?
Bile acids activate FXR, which then represses CYP7A1 and related biosynthetic genes, closing a negative feedback loop that limits bile acid production.
How does the gut microbiota affect bile acid biosynthesis?
Microbes modify bile acids and change the levels of FXR antagonists such as tauro-beta-muricholic acid, thereby tuning the strength of the feedback signal.
What happens when negative regulation of bile acid biosynthesis fails?
Bile acids accumulate, causing hypercholanemia and cholestatic injury, and can trigger inflammatory responses such as NLRP3 inflammasome activation.
Is GO:0070858 relevant to cancer?
Yes, microbiota-modified bile acids can promote colorectal cancer growth by suppressing CD8+ T cell effector functions, linking this pathway to tumor immunity.
Which experimental models are used to study this process?
CRISPR knockout, point-mutation, knock-in and overexpression models, combined with bile acid profiling and transcriptomics, are commonly used.
What is the role of SLC10A5 in bile acid regulation?
SLC10A5 deficiency causes hypercholanemia, showing that transporter function is required for normal bile acid handling and feedback.
How is bile acid biosynthesis measured in the lab?
LC-MS bile acid profiling and RT-qPCR of CYP7A1 and FXR target genes are standard readouts of pathway activity and repression.
Can CRISPR screens identify new regulators of bile acid biosynthesis?
Yes, pooled and arrayed CRISPR screens can uncover new modifiers of the FXR feedback axis and bile acid transport, which can then be validated in focused models.
Conclusion
GO:0070858, negative regulation of bile acid biosynthetic process, is a mechanistically rich biological process centered on FXR-mediated feedback, microbiota-dependent tuning and transporter-controlled bile acid load. Its failure causes hypercholanemia, cholestatic inflammation and metabolic disturbance, while its manipulation influences obesity-related glucose control and anti-tumor immunity. Because the pathway is genetically tractable, CRISPR knockout, point-mutation, knock-in and overexpression models remain the most reliable way to establish causality among candidate regulators.
References
- 1. Hao H et al.. 2017. Farnesoid X Receptor Regulation of the NLRP3 Inflammasome Underlies Cholestasis-Associated Sepsis.. Cell Metab 25(4):856-867.e5 PMID: 28380377
- 2. Cong J et al.. 2024. Bile acids modified by the intestinal microbiota promote colorectal cancer growth by suppressing CD8(+) T cell effector functions.. Immunity 57(4):876-889.e11 PMID: 38479384
- 3. Won TH et al.. 2025. Host metabolism balances microbial regulation of bile acid signalling.. Nature 638(8049):216-224 PMID: 39779854
- 4. Sayin SI et al.. 2013. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist.. Cell Metab 17(2):225-35 PMID: 23395169
- 5. Münzker J et al.. 2022. Functional changes of the gastric bypass microbiota reactivate thermogenic adipose tissue and systemic glucose control via intestinal FXR-TGR5 crosstalk in diet-induced obesity.. Microbiome 10(1):96 PMID: 35739571
- 6. Labiano I et al.. 2022. TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation.. J Hepatol 77(4):991-1004 PMID: 35750136
- 7. Xu Y et al.. 2025. SLC10A5 deficiency causes hypercholanemia.. Hepatology 81(2):408-422 PMID: 38986003
- 8. Ye X et al.. 2022. FXR Signaling-Mediated Bile Acid Metabolism Is Critical for Alleviation of Cholesterol Gallstones by Lactobacillus Strains.. Microbiol Spectr 10(5):e0051822 PMID: 36036629
